ClinicalTrials.gg
CompletedNCT04163393R-EVOLUTIONUpdated Feb 8, 2022

R-One Efficiency For PCI Evolution With Robotic Assistance

An interventional study of Percutaneous Coronary Intervention and Percutaneous Coronary Intervention using R-One assistance in Coronary Artery Disease and Percutaneous Coronary Intervention, sponsored by Robocath. Completed at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-08.

Sponsored by Robocath · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 218 studies in Coronary Artery Disease with a site in France — 28 open to participants now, 44 under way, 6 of them phase 3. Coronary Artery Disease · France.

Enrollment
125th of 158
62 · median 300
Started
2019
with 7 others
No phase
89 of 218
15 open now
Registered
159th of 218
by date

Among the 218 studies in Coronary Artery Disease with a site in France, this one is the 125th largest by enrollment of the 158 interventional ones that give a count, is one of 8 that started in 2019, is one of 89 with no phase, and was the 159th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

28 of the 218 studies in Coronary Artery Disease with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies in Coronary Artery Disease with a site in France, or all of them as a file.
02

Study summary

This study is a Prospective, Multi-center, Single-arm clinical study, in patients with Coronary Artery Disease, including patients with silent ischemia (excluding STEMI), who qualify for elective Percutaneous Coronary Intervention (PCI), aimed to assess the Safety and Efficacy of the R-One device in elective PCI.

03

Conditions studied

  • Coronary Artery Disease
  • Percutaneous Coronary Intervention

Keywords

  • Coronary Artery Disease
  • Percutaneous Coronary Intervention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years;
  • Candidate for PCI;
  • Presence of a de novo coronary artery stenosis of ≥ 50% and \<100% in a native coronary artery indicated and suitable for stent implantation;
  • The vessel has a reference vessel diameter ranging from 2.5 mm to 4.0 mm;
  • The target lesion length allows for treatment with a single stent up to 38 mm in length;
  • Up to 2 target vessels each with a single target lesion requiring a single stent per lesion and treatable within a single procedure may be included (no further staged procedure allowed);
  • The patient provides written as approved by the applicable Ethics Committee and is willing to comply with all study requirements including 30 days follow-up.

Exclusion criteria

Exclusion Criteria:

  • Target lesion has TIMI flow \< 3;
  • Treatment of in-stent restenosis, or prior stent in the target vessel proximal to the target lesion;
  • More than one target lesion per vessel requiring treatment at the time of procedure;
  • Target lesion is a bifurcation requiring balloon or stent implantation of the side branch, with a side-branch RVD of ≥1.5 mm with a DS ≥50% at or within 5 mm its origin, or RVD ≥2.0 mm regardless of the presence of side branch disease;
  • Target lesion is located in left main coronary artery, or any left main stenosis > 30%;
  • Target lesion is within 5 mm of the ostial LAD, ostial LCX or ostial RCA;
  • Severe vessel tortuosity;
  • Severe vessel calcification;
  • STEMI, cardiopulmonary resuscitation or cardiogenic shock within 48 hours of the procedure;
  • Presence of visible thrombus;
  • Need for any procedure other than balloon angioplasty or stenting (e.g. atherectomy, laser, are excluded);
  • Patients under judicial protection, tutorship or curatorship (for France only);
  • Any patient participating in another clinical study evaluating a drug or a medical device (except registries for which the primary endpoint has not been evaluated;
  • Pregnant and breast-feeding women or intention to become pregnant prior to completion of all follow-up procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    R-One

    Patients treated with robotic assistance

    Procedure: Percutaneous Coronary Intervention · Device: Percutaneous Coronary Intervention using R-One assistance

Interventions

  • ProcedurePercutaneous Coronary Intervention

    PCI with robotic assistance

  • DevicePercutaneous Coronary Intervention using R-One assistance

    PCI with robotic assistance

06

What researchers measure

Primary outcomes

  1. Safety Endpoint: Number of patients with absence of Intra-procedural complications (Dissection, Thrombus, Air embolus, traumatic aorta)

    Absence of Intra-procedural complications (Dissection \>/= NHLBI type D, perforation, decrease of TIMI flow (\</= 2), acute occlusion, visible thrombus formation, significant air embolus, traumatic aortic or Left Main dissection by guiding catheter

    Time frame: Peri-procedure

  2. Efficacy Endpoint: Number of Patients with Procedure technical success

    Procedure technical success defined as the successful advancement and retraction of all PCI devices (guidewires, balloon catheters and stents) and the successful treatment of all the target lesions using the R-One system and without conversion to manual operation

    Time frame: During Procedure

Secondary outcomes

  1. Number of patients with Absence of each type of Intra-procedural complication (Dissection, Thrombus, Air embolus, traumatic aorta)

    Component of the Primary Safety Endpoint: Absence of Intra-procedural complications (Dissection \>/= NHLBI type D, perforation, decrease of TIMI flow (\</= 2), acute occlusion, visible thrombus formation, significant air embolus, traumatic aortic or Left Main dissection by guiding catheter

    Time frame: During Procedure

  2. Procedure duration

    Time between arterial sheath introduction and sheath removal

    Time frame: During Procedure

  3. Robot duration

    From the time when the robot begins to manipulate the guidewire to the time when the last guidewire is removed

    Time frame: During Procedure

  4. Radiation exposure using dosimeters (Patient Radiation, Robot Dose, Procedure Dose)

    Patient and Operator

    Time frame: During Procedure

  5. Contrast Volume in mL

    Measure of the volume of injected contrast media

    Time frame: During Procedure

  6. Rate of Bleeding or Vascular Complications

    BARC definition

    Time frame: Up to 1 month

  7. Rate of Device Oriented Composite Criteria (Cardiovascular Death, Myocardial Infarction (peri-procedural and spontaneous), non clearly attributed to a non target or clinically driven target lesion revascularization)

    ARC 2 definition: Cardiovascular Death, Myocardial Infarction (peri-procedural and spontaneous), non clearly attributed to a non target or clinically driven target lesion revascularization

    Time frame: Post-Procedure, 1 month

07

Study locations

6 sites
  • Het Ziekenhuisnetwerk Antwerpen vzw
    Antwerpen, 2000, Belgium
  • CHU Caen Normandie
    Caen, 14033, France
  • CHU Rouen
    Rouen, 76000, France
  • Clinique Pasteur
    Toulouse, 31076, France
  • INCCI
    Luxembourg, L-1210, Luxembourg
  • Maastad Ziekenhuis
    Rotterdam, 3079, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Nov 2021, 25 months.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's 25 months is close to that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2019
First posted
Nov 14, 2019
StartActual
Sep 17, 2019
Primary completionActual
Nov 8, 2021
CompletionActual
Dec 15, 2021
Last update
Feb 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04163393
Lead sponsor
Robocath
Responsible party
Sponsor
First posted
Nov 14, 2019
Start date
Sep 17, 2019
Primary completion
Nov 8, 2021
Completion
Dec 15, 2021
Last update
Feb 8, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion